MET and non-small cell lung carcinoma: In addition to crizotinib, the potential effectiveness of more selective MET-TKIs, including capmatinib, savolitinib, and tepotinib, combined with any EGFR-TKIs in the management of patients with EGFR-mutant, MET-amplified NSCLC has been demonstrated in several prospective clinical studies (21, 24–26, 28).